In a report published Wednesday, Piper Jaffray analyst David Amsellem upgraded the rating on Endo Health Solutions ENDP from Underweight to Neutral, and raised the price target from $26.00 to $58.00.
In the report, Piper Jaffray noted, “With Endo announcing its plans to acquire Paladin Labs for $1.6B in a mostly stock-based transaction, we are upgrading ENDP to a Neutral from an Underweight and raising our PT to $58 from $26. Beyond the EPS accretion, the potential for additional accretive M&A in the context of a tax-efficient structure (a 2014 pro forma tax rate of near 20% vs. 28% in 2013) should enable ENDP to sustain a more robust P/E in our view. Further, we believe the cost synergies and tax efficiencies point to far more visibility on a diluted EPS trough north of $4.00 even with multiple Lidoderm generics, further enabling a sustainable one-year forward P/E that is closer to the mid-teens average seen for ENDP's peer group. Our new PT is based on a P/E of 14x our 2015 pro forma EPS estimate of $4.35, discounted 0.5 years at 10%.”
Endo Health Solutions closed on Tuesday at $56.22.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in